EUVIMEDEUVIMED entdecken
Crossref

The Role of GLP-1 Receptor Agonists in Obesity Management: Evidence from Glycemic and Non-Glycemic Populations

Ayushi Jain, Yashashwi Shrivastav, Nimita Manocha, Gouri Baraskar, Rekha Bisht, Deepika Bhawsar, Nisha Retrekar

International Journal of Drug Delivery Technology · 19.05.2026 · 16 (30s)

DOI: 10.25258/ijddt.16.30s.55 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 19.05.2026. Verfasst von Ayushi Jain und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a Multifactorial, Chronic illness that is typified by an excess adiposity and is accompanied by metabolic, cardiovascular, and systemic complications. It is increasingly becoming common all over the world, which accentuates the necessity of efficient and long- lasting therapeutic methods. The typical management strategies, such as lifestyle change, pharmacotherapy, and bariatric surgery, are usually limited either by low levels of long- term compliance, limited effectiveness or low availability. Here, incretin hormone glucagon-like peptide-1 (GLP-1) that plays a role in the regulation of glucose levels and appetite has become an important therapeutic target. GLP- 1 receptor agonists (GLP- 1RAs) emulate the endogenous GLP- 1 activity and have a pleiotropic effect, such as stimulating glucose- dependent insulin release, inhibiting glucagon release, slowing gastric emptying, and reducing central appetite. All these mechanisms play a role in the enhancement of glycemic control and considerable weight loss. It has been shown in clinical trials that GLP- 1RAs, including liraglutide and semaglutide, can result in significant weight loss and body weight reduction in patients with type 2 diabetes, as well as significant weight loss advantages in non-diabetic groups. New dual and triple incretin agonists, such as tirzepatide and retatrutide, also increase the therapeutic effect, showing a better response in weight loss and metabolism. Although they have positive efficacy, GLP-1RAs have gastrointestinal adverse effects that are usually temporary and can be controlled. Altogether, incretin-based therapies are a revolutionary breakthrough in obesity treatment, which can be doubly beneficial in terms of weight loss and metabolic well-being. The review identifies the mechanistic foundations, clinical effectiveness, and the emerging therapeutic potential of GLP-1-based interventions, as a means of dealing with the worldwide obesity crisis.

Zitieren

APA

Jain, A., Shrivastav, Y., Manocha, N., Baraskar, G., Bisht, R., Bhawsar, D., & Retrekar, N. (2026). The Role of GLP-1 Receptor Agonists in Obesity Management: Evidence from Glycemic and Non-Glycemic Populations. International Journal of Drug Delivery Technology, 16(30s). https://doi.org/10.25258/ijddt.16.30s.55

Vancouver

Jain A, Shrivastav Y, Manocha N, Baraskar G, Bisht R, Bhawsar D, et al. The Role of GLP-1 Receptor Agonists in Obesity Management: Evidence from Glycemic and Non-Glycemic Populations. International Journal of Drug Delivery Technology. 2026;16(30s). doi:10.25258/ijddt.16.30s.55

BibTeX
@article{Jain2026,
  author = {Jain, Ayushi and Shrivastav, Yashashwi and Manocha, Nimita and Baraskar, Gouri and Bisht, Rekha and Bhawsar, Deepika and Retrekar, Nisha},
  title = {The Role of GLP-1 Receptor Agonists in Obesity Management: Evidence from Glycemic and Non-Glycemic Populations},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {30s},
  doi = {10.25258/ijddt.16.30s.55}
}
Kostenlos starten →